RxDoctor Payments Data

Ngoc Phan, DO

Internal Medicine · Lilburn, GANPI 1215299086

Payments from drug & device makers

$543in general payments, 2019–2025

Across 31 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$230
  • Pfizer$119
  • Amgen$49
  • GSK$37
  • AstraZeneca$34
  • Boehringer Ingelheim$20
  • plus $53 from 3 others

What the payments were for

  • Food & beverage$543100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$543 in reported general payments places this provider in the 55th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$70,536
Medicare patients
114
Services billed
942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate79$104,849
RybelsusSemaglutide33$86,346
ProliaDenosumab34$59,080
JardianceEmpagliflozin36$55,082
Metformin Er GastricMetformin Hcl24$43,052
LinzessLinaclotide33$42,421
TrulicityDulaglutide11$28,936
EliquisApixaban18$28,884
FarxigaDapagliflozin Propanediol17$25,466
MyrbetriqMirabegron32$24,622
Diclofenac Epolamine13$21,674
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$21,641
RestasisCyclosporine14$19,680
OzempicSemaglutide12$17,231
VascepaIcosapent Ethyl18$13,889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$230$103,57745 claims
AmgenProlia$49$59,08034 claims
Boehringer IngelheimJardiance$20$55,08236 claims
PfizerEliquis$119$28,88418 claims
AstraZenecaFarxiga$34$25,46617 claims
GSKTrelegy Ellipta, Shingrix$37$24,98533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Lilburn

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →